Sign in
CompletedPhase 2

Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder

Key facts

Who runs it
Anders Fink-Jensen, MD, DMSci
Where
Denmark1 site in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
60 people enrolled
Started
1 Sept 2023
Ended
22 Dec 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Psilocybin
  • Maltodextrin
Record updated
24 March 2026

Who can take part

Age
20 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Bodyweight of 50-110 kg
  • AUD according to DSM-5 criteria and alcohol dependence according to ICD-10
  • AUD Identification Test (AUDIT) ≥ 15
  • ≥ 5 heavy drinking days in the past 28 days prior to inclusion

Who cannot take part

  • Current or previously diagnosed with any psychotic disorder or bipolar affective disorder
  • Treatment with disulfiram, naltrexone, acamprosate and nalmefene within 28 days of inclusion
  • Treatment with any serotonergic medication or drugs within one month prior inclusion
  • Immediate family member with a diagnosed psychotic disorder
  • History of delirium tremens or alcohol withdrawal seizures
  • History of suicide attempt or present suicidal ideation at screening
  • Present or former severe neurological disease including trauma with loss of consciousness > 30 min
  • Cardiovascular disease defined as decompensated heart failure (NYHA class III or IV), unstable angina pectoris, myocardial infarction within the last 12 months or uncontrolled hypertension (systolic blood pressure >165 mmHg, diastolic blood pressure >95 mmHg)
  • Any oOther active substance use disorders (except nicotine) defined as a Drug Use Disorder Identification Test score >six/two (men/women) and investigator's clinical evaluation
  • Any other condition that the clinician estimates can interfere with trial participation
  • Impaired hepatic function (alanine transaminase >210/135 units/l men/women)
  • Present or former abnormal QTc (>450/470 ms men/women)
  • Withdrawal symptoms at screening (>nine on the Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) (43)
  • Women who are pregnant, breastfeeding, or intend to become pregnant or are not using adequate contraceptive measures considered highly effective (44)
  • Unable to speak or understand Danish

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Note: The trial is only eligible for citizens of Denmark.

Read full original descriptionShow less

The purpose of this project is to assess the treatment efficacy of a single high dose of psilocybin administered within a protocol of psychological support to patients diagnosed with alcohol use disorder (AUD).

The 2 groups in the trial

  • Psilocybin-assisted therapyTreatment being tested

    45 patients will receive a single administration of 25mg psilocybin given in a protocol of psychological support before, during and after dosing.

    Treatment: Psilocybin

  • Placebo-assisted therapyPlacebo, for comparison

    45 patients will receive a single administration of placebo (lactose) given in a protocol of psychological support before, during and after dosing.

    Treatment: Maltodextrin

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.
Publications
Record updated
24 March 2026